GlassScriptPhysician profile
Hillary D Davis
NPI 1285362913
$6,196.72
in general payments reported to CMS, 2019-2025
45 companies · $2,701 in 2025
The $2,701 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,077 · 2024: $2,419 · 2025: $2,701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,635 · Education: $562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,634.81 |
| Education | $561.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $773.95 | 2023-2025 | Rybrevant, Darzalex, Tecvayli |
| Daiichi Sankyo INC. | $625.68 | 2023-2025 | Enhertu, Injectafer, Datroway |
| Novartis Pharmaceuticals Corporation | $572.00 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $420.96 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $391.12 | 2023-2025 | Imfinzi, Enhertu, Faslodex |
| Exelixis INC. | $345.93 | 2023-2025 | Cabometyx |
| Incyte Corporation | $296.08 | 2023-2025 | Monjuvi, Jakafi |
| Takeda Pharmaceuticals U.S.A., INC. | $280.31 | 2023-2025 | Ninlaro, Iclusig, Alunbrig |
| Eisai INC. | $234.94 | 2023-2025 | |
| Abbvie INC. | $194.45 | 2024-2025 | |
| Pfizer INC. | $171.54 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $166.65 | 2023-2025 | Libtayo |
| Lilly USA, LLC | $141.40 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Seagen INC. | $129.53 | 2023-2025 | Tukysa |
| Glaxosmithkline, LLC. | $127.03 | 2023-2025 | Ojjaara |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iovance Biotherapeutics, INC. | $103.64 | 2024-2025 | Amtagvi |
| Bayer Healthcare Pharmaceuticals INC. | $94.11 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $91.47 | 2023-2025 | Onivyde, Tazverik |
| Deciphera Pharmaceuticals INC. | $89.40 | 2023-2025 | Qinlock, Romvimza |
| Beone Medicines USA, INC. | $80.37 | 2025 | Brukinsa |
| G1 Therapeutics, INC. | $79.71 | 2023 | Cosela |
| Aveo Pharmaceuticals, INC. | $70.11 | 2024-2025 | |
| Genzyme Corporation | $70.09 | 2023-2024 | |
| Emd Serono, INC. | $65.52 | 2024 | |
| Genentech USA, INC. | $58.16 | 2023-2024 | Phesgo, Perjeta, Venclexta |
| Pharmacosmos Therapeutics INC. | $54.98 | 2024 | Monoferric, Cosela |
| Pharmaessentia USA Corporation | $53.29 | 2023-2024 | Besremi |
| Kyowa Kirin, INC. | $45.58 | 2025 | |
| Beigene USA, INC. | $33.33 | 2024 | Brukinsa |
| Amgen INC. | $32.38 | 2023 | Prolia, Evenity, Lumakras |
| Array Biopharma INC | $32.25 | 2023-2025 | Mektovi, Lorbrena, Braftovi |
| Puma Biotechnology, INC. | $31.05 | 2023-2024 | Nerlynx |
| Sumitomo Pharma America, INC. | $29.57 | 2025 | Orgovyx |
| Caris Mpi, INC. | $29.49 | 2025 | Mi Cancer Seek |
| Tersera Therapeutics LLC | $22.26 | 2025 | Zoladex |
| Tempus Ai, INC | $20.12 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.56 | 2025 | |
| Azurity Pharmaceuticals, INC. | $18.32 | 2024 | Vivimusta |
| E.R. Squibb & Sons, L.L.C. | $18.11 | 2024 | Opdivo |
| Alnylam Pharmaceuticals INC. | $15.30 | 2025 | Givlaari |
| Acrotech Biopharma INC. | $15.10 | 2024 | Beleodaq |
| Geron Corporation | $15.04 | 2025 | Rytelo |
| Sobi, INC | $14.98 | 2025 | |
| Syndax Pharmaceuticals, INC. | $13.65 | 2025 | |
| Rigel Pharmaceuticals, INC. | $8.21 | 2024 | Rezlidhia, Tavalisse |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hillary Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.